MedTrace Logo

DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)

NCT00664066 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2021-06-25

Study results available
· View outcomes & findings →

Summary

This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common adverse drug reactions, and to summarise DYNEPO drug utilisation.

Conditions

Interventions

DRUG

DYNEPO (epoetin delta)

dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-25
Primary Completion
2008-07-30
Completion
2008-07-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00664066 on ClinicalTrials.gov